Akèy › Maladi otoim › Kalifòni
Etid klinik pou Maladi otoim nan Kalifòni
27 etid pou Maladi otoim ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- Los Angeles12 etid
- Orange7 etid
- San Francisco7 etid
- Mountain View6 etid
- San Diego5 etid
- Sacramento5 etid
- Irvine3 etid
Tèks ofisyèl etid la (Anglè)
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- City of Hope Comprehensive Cancer Center, Duarte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06817889A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Chula Vista
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Sep 25, 2026 · NCT07541287Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of California Irvine - Accepting Adult Patients, Orange
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients, San Francisco
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- University of Southern California, Los Angeles
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 11, 2026 · NCT07059000A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Orange
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of California Irvine, Orange
- UC Davis Health, Sacramento
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- University of California Irvine, Orange
- UC Davis, Department of Neurology, Sacramento
- University of California, San Francisco, San Francisco
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Aug 13, 2026 · NCT06359041A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- UC Irvine, Irvine
- Orso Health, La Jolla
- University of California, Los Angeles-UCLA, Los Angeles
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-103, South Gate
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Jul 31, 2026 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1010, Carlsbad
- Site Number - 1028, Irvine
- Site Number - 1023, Los Angeles
- ak 2 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Ronald Reagan UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford University Medical Center, Palo Alto
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Jul 29, 2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- City of Hope, Duarte
- Children's Hospital of Los Angeles, Glendale
- Scripps Green Hospital, La Jolla
- ak 8 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- UCSF Medical Center, San Francisco
- Stanford Medical Center, Stanford
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Jun 30, 2026 · NCT06201416Atacicept in Multiple Glomerular Diseases
- Vera Therapeutics, Brisbane
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou Jun 26, 2026 · NCT06983028A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Stanford University, Dept. of Dermatology, Redwood City
- UC Davis, Dept. of Dermatology, Sacramento
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 29, 2026 · NCT04422912A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- ak 2 plis
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- Stanford Multiple Sclerosis Center, Palo Alto
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Feb 27, 2026 · NCT06138132A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford Hospital, Palo Alto
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT06626919Central Vein Sign in Multiple Sclerosis Extension Study
- Cedars-Sinai Medical Center, Los Angeles
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Feb 20, 2026 · NCT07424027CD4^LVFOXP3 in Participants With IPEX
- Lucile Packard Children's Hospital, Palo Alto
Ap rekriteFaz 1
4 Months – 35 Years · Gason · Mizajou May 22, 2025 · NCT05241444Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
- University of California, San Diego, La Jolla
Ap rekriteEtid obsèvasyon
Tout laj · Fanm · Mizajou Jan 28, 2025 · NCT02103361Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
- MiraKind, Los Angeles
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jan 23, 2025 · NCT02253251Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Apr 29, 2022 · NCT04684602Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.